PLIANT THERAPEUTICS, INC. Lease, Cost
PLIANT THERAPEUTICS, INC. (PLRX) reported Lease, Cost of $1.98 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-08-11
- PLIANT THERAPEUTICS, INC. lease, cost for the quarter ending 2026-06-30 was $1.98M, a 2.52% decline year-over-year.
- PLIANT THERAPEUTICS, INC. lease, cost for the quarter ending 2026-03-31 was $2.01M, a 3.62% increase year-over-year.
- PLIANT THERAPEUTICS, INC. lease, cost for the quarter ending 2025-12-31 was $1.99M, a 1.34% decline year-over-year.
- PLIANT THERAPEUTICS, INC. lease, cost for the quarter ending 2025-09-30 was $2.02M, a 0.25% increase year-over-year.
- PLIANT THERAPEUTICS, INC. lease, cost for fiscal 2025 was $7.97M, a 10.90% increase from fiscal 2024.
- PLIANT THERAPEUTICS, INC. lease, cost for fiscal 2024 was $7.18M, a 103.11% increase from fiscal 2023.
- PLIANT THERAPEUTICS, INC. lease, cost for fiscal 2023 was $3.54M, a 9.78% increase from fiscal 2022.
- PLIANT THERAPEUTICS, INC. lease, cost for fiscal 2022 was $3.22M, a 0.83% decline from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.98M 10-Q · filed 2026-08-11 | $3.98M 10-Q · filed 2026-08-11 | $5.97M derived: sum of 3 quarters · filed 2026-08-11 | $7.99M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $2.01M 10-Q · filed 2026-05-11 | $3.99M derived: sum of 2 quarters · filed 2026-05-11 | $6.01M derived: sum of 3 quarters · filed 2026-05-11 | $8.04M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $1.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $4.00M derived: sum of 2 quarters · filed 2026-03-11 | $6.03M derived: sum of 3 quarters · filed 2026-08-11 | $7.97M 10-K · filed 2026-03-11 |
| 2025-09-30 | $2.02M 10-Q · filed 2025-11-06 | $4.04M derived: sum of 2 quarters · filed 2026-08-11 | $5.98M 10-Q · filed 2025-11-06 | $7.99M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $2.03M 10-Q · filed 2026-08-11 | $3.96M 10-Q · filed 2026-08-11 | $5.98M derived: sum of 3 quarters · filed 2026-08-11 | $7.99M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $1.94M 10-Q · filed 2026-05-11 | $3.95M derived: sum of 2 quarters · filed 2026-05-11 | $5.96M derived: sum of 3 quarters · filed 2026-05-11 | $7.87M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $2.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $4.03M derived: sum of 2 quarters · filed 2026-03-11 | $5.93M derived: sum of 3 quarters · filed 2026-03-11 | $7.18M 10-K · filed 2026-03-11 |
| 2024-09-30 | $2.01M 10-Q · filed 2025-11-06 | $3.92M derived: sum of 2 quarters · filed 2025-11-06 | $5.17M 10-Q · filed 2025-11-06 | $5.83M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $1.91M 10-Q · filed 2025-08-07 | $3.04M 10-Q · filed 2025-08-07 | $3.82M derived: sum of 3 quarters · filed 2025-08-07 | $4.64M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $1.14M 10-Q · filed 2025-05-08 | $1.91M derived: sum of 2 quarters · filed 2025-05-08 | $2.74M derived: sum of 3 quarters · filed 2025-05-08 | $3.64M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $775.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $1.60M derived: sum of 2 quarters · filed 2025-03-03 | $2.50M derived: sum of 3 quarters · filed 2025-03-03 | $3.54M 10-K · filed 2025-03-03 |
| 2023-09-30 | $828.00K 10-Q · filed 2024-11-07 | $1.73M derived: sum of 2 quarters · filed 2024-11-07 | $2.76M 10-Q · filed 2024-11-07 | $3.77M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $902.00K 10-Q · filed 2024-08-07 | $1.92M 10-Q · filed 2024-08-07 | $2.95M derived: sum of 3 quarters · filed 2025-03-03 | $3.73M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $1.01M 10-Q · filed 2024-05-06 | $2.04M derived: sum of 2 quarters · filed 2025-03-03 | $2.83M derived: sum of 3 quarters · filed 2025-03-03 | |
| 2022-12-31 | $1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $1.82M derived: sum of 2 quarters · filed 2025-03-03 | $3.22M 10-K · filed 2025-03-03 | |
| 2022-09-30 | $786.00K 10-Q · filed 2023-11-09 | $2.19M 10-Q · filed 2023-11-09 | ||
| 2021-12-31 | $3.25M 10-K · filed 2024-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |